Commentary: Role of Bone-Modifying Agents in Metastatic Breast Cancer

Por Hortobagyi, Gabriel N.
Publicado em 2011

Toward Individualized Breast Cancer Therapy: Translating Biological Concepts to the Bedside

Por Hortobagyi, Gabriel N.
Publicado em 2012

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2()

Por Hortobagyi, Gabriel N.
Publicado no Neoplasia (2015)

Inflammatory breast cancer: Clinical progress and the main problems that must be addressed

Por Giordano, Sharon H, Hortobagyi, Gabriel N
Publicado em 2003

Prognostic molecular markers in early breast cancer

Por Esteva, Francisco J, Hortobagyi, Gabriel N
Publicado em 2004

Fingerprinting Lymph Node Metastases

Por Symmans, W. Fraser, Hortobagyi, Gabriel N.
Publicado em 2008

Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer

Por Alvarez, Ricardo H., Hortobagyi, Gabriel N.
Publicado em 2013

Hot Flashes: A Review of Pathophysiology and Treatment Modalities

Por Morrow, Phuong Khanh H., Mattair, Danielle N., Hortobagyi, Gabriel N.
Publicado em 2011

Impact of Diabetes Mellitus on Complications and Outcomes of Adjuvant Chemotherapy in Older Patients With Breast Cancer

Por Srokowski, Tomasz P., Fang, Shenying, Hortobagyi, Gabriel N., Giordano, Sharon H.
Publicado em 2009

Overweight, Obesity, Diabetes, and Risk of Breast Cancer: Interlocking Pieces of the Puzzle

Por La Vecchia, Carlo, Giordano, Sharon H., Hortobagyi, Gabriel N., Chabner, Bruce
Publicado em 2011

First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validat...

Por Rivera, Edgardo, Haim Erder, M, Fridman, Moshe, Frye, Debra, Hortobagyi, Gabriel N
Publicado em 2003

Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review

Por Dawood, Shaheenah, Broglio, Kristine, Buzdar, Aman U., Hortobagyi, Gabriel N., Giordano, Sharon H.
Publicado em 2010

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt

Por Bartholomeusz, Chandra, Yamasaki, Fumiyuki, Saso, Hitomi, Kurisu, Kaoru, Hortobagyi, Gabriel N., Ueno, Naoto T.
Publicado em 2011

Role of Epidermal Growth Factor Receptor in Breast Cancer

Por Masuda, Hiroko, Zhang, Dongwei, Bartholomeusz, Chandra, Doihara, Hiroyoshi, Hortobagyi, Gabriel N., Ueno, Naoto T.
Publicado em 2012

Decline in the Use of Anthracyclines for Breast Cancer

Por Giordano, Sharon H., Lin, Yu-Li, Kuo, Yong Fang, Hortobagyi, Gabriel N., Goodwin, James S.
Publicado em 2012

Letters to the Editor

Por Broadwater, J. Ralph, Edwards, Michael J., Hortobagyi, Gabriel N., Ames, Fred C., Blach, Charles M.
Publicado em 1992

Impact of a Scientific Presentation on Community Treatment Patterns for Primary Breast Cancer

Por Giordano, Sharon H., Duan, Zhigang, Kuo, Yong-Fang, Hortobagyi, Gabriel N., Freeman, Jean, Goodwin, James S.
Publicado em 2006

Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity

Por Yamasaki, Fumiyuki, Zhang, Dongwei, Bartholomeusz, Chandra, Sudo, Tamotsu, Hortobagyi, Gabriel N., Kurisu, Kaoru, Ueno, Naoto T.
Publicado em 2007

Limits of Observational Data in Determining Outcomes From Cancer Therapy

Por Giordano, Sharon H., Kuo, Yong-Fang, Duan, Zhigang, Hortobagyi, Gabriel N., Freeman, Jean, Goodwin, James S.
Publicado em 2008

Male breast cancer according to tumor subtype and race: a population based study

Por Chavez-MacGregor, Mariana, Clarke, Christina A., Lichtensztajn, Daphne, Hortobagyi, Gabriel N., Giordano, Sharon H.
Publicado em 2013